Mar 10, 2017 13:00 pm UTC| Business
Collaboration pairs leading SMDC technology with recognized CAR T-cell research expert Plans to develop next generation CAR T-cell therapeutic platform with potential for improved safety and efficacy in solid tumor...
Jounce Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results
Mar 10, 2017 13:00 pm UTC| Business
- Completed upsized initial public offering raising $117.1 million in gross proceeds - - Continue to advance lead product candidate JTX-2011 through Phase 1/2 ICONIC trial and to broaden new drug candidate pipeline...
The VisionCenter of West Texas Certified by the Dry Eye Center of Excellence
Mar 10, 2017 13:00 pm UTC| Business
LUBBOCK, Texas, March 10, 2017 -- The VisionCenter of West Texas has announced that they are a recipient of the Dry Eye Center of Excellence certification. This recognizes The VisionCenter as one of the authorized...
Mar 10, 2017 13:00 pm UTC| Business
BURLINGAME, Calif., March 10, 2017 -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today...
Hurco Reports First Quarter Results for Fiscal 2017
Mar 10, 2017 13:00 pm UTC| Business
INDIANAPOLIS, March 10, 2017 -- Hurco Companies, Inc. (Nasdaq:HURC) today reported results for the first fiscal quarter ended January 31, 2017. Hurco recorded net income of $879,000, or $0.13 per diluted share, for the...
Federated National Holding Company Authorizes Additional $10 Million Share Repurchase Program
Mar 10, 2017 13:00 pm UTC| Business
SUNRISE, Fla., March 10, 2017 -- Federated National Holding Company (“the “Company”) (NASDAQ:FNHC), an insurance holding company, announced today that its Board of Directors authorized an additional share repurchase...
Bio-Path Holdings to Present Data at the 2017 AACR Annual Meeting
Mar 10, 2017 13:00 pm UTC| Business
HOUSTON, March 10, 2017 -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic...